For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 13,314 | |||
| General and administrative | 15,411 | |||
| Total operating expenses | 28,725 | |||
| Loss from operations | -28,725 | |||
| Change in fair value of warrant derivative | -153 | |||
| Fair value loss from standby equity purchase agreement (sepa arrangement) | -388 | |||
| Foreign exchange (loss) gain | -106 | |||
| Interest income | 386 | |||
| Total other income, net | 45 | |||
| Loss before income taxes | -28,680 | |||
| Income tax expense | 79 | |||
| Net loss | -28,759 | |||
| Translation adjustments | -136 | |||
| Comprehensive loss | -28,895 | |||
| Basic EPS | -0.3 | |||
| Diluted EPS | -0.3 | |||
| Basic Average Shares | 95,857,147 | |||
| Diluted Average Shares | 95,857,147 | |||
ONCOLYTICS BIOTECH INC (ONCY)
ONCOLYTICS BIOTECH INC (ONCY)